5 ml semaglutide: understanding the volume in your Wegovy pen

Step 1 — Read the label correctly: volume versus concentration

When you look at a Wegovy pen, you'll see two figures that are easy to conflate. The first is the fill volume: how many millilitres of liquid the pen cartridge holds. For Wegovy, that is 3 ml per pen, which is the standard fill volume you'll find explained in detail if you want to understand what that figure means in practice. The second is the concentration, expressed as mg/ml. Depending on the dose strength, the concentration of semaglutide dissolved in those 3 ml changes. A 0.25 mg weekly dose is delivered from a much lower concentration than a 2.4 mg maintenance dose.

The phrase "5 ml semaglutide" is most likely a misreading of a concentration figure, a label from an unrelated formulation, or a description of a multi-dose vial used in research or compounding contexts. None of those apply to the licensed Wegovy pre-filled pen dispensed in the UK. The Wegovy pen format is factory-set and pre-measured; you don't draw up a syringe, and you don't measure volume yourself. Each weekly injection is a single click. The pen tracks remaining doses internally.

This matters because patients sometimes worry they have the wrong pen, or have been given less medicine than expected, when they count the millilitres. The millilitre count is not the dose. Your prescriber and the Patient Information Leaflet confirm what the weekly dose is, not the fill volume printed on the side.

Step 2, How Wegovy moves through its dose schedule

The MHRA-approved titration pathway for Wegovy starts at 0.25 mg weekly and increases in stages, typically every four weeks, through 0.5 mg, 1 mg and 1.7 mg, and if you're curious about what the 1 ml semaglutide format involves at that point in the schedule, that page goes into the detail before reaching the standard 2.4 mg maintenance dose. A higher 7.2 mg option was approved by the MHRA in January 2026 and a dedicated single-dose 7.2 mg pen received approval in April 2026, for adults with a BMI of 30 or above.

At each stage, the pen is a different product: different concentration, different injection volume per click, same 3 ml cartridge. A patient on 0.25 mg is not receiving less liquid than a patient on 2.4 mg in any meaningful clinical sense; the pen delivers the programmed dose accurately regardless. NHS guidance on semaglutide explains this distinction clearly and is worth bookmarking for reference between clinic contacts.

The schedule is not something to self-manage. Increasing sooner than advised, or swapping pens from a different dose tier, changes the amount of drug delivered per injection. A clinical review sits behind every step. That is why a named prescriber, not software, reads through your consultation answers before any dose change is confirmed.

Step 3, Storing your pen and fitting it into daily life

Unopened Wegovy pens are stored in the fridge at 2–8°C. Many people keep them in the fridge door, which is convenient, though the Patient Information Leaflet gives the exact storage parameters and should be your final word on this, including how long a pen can sit at room temperature once you've taken it out. Once in use, storage conditions can change; check the leaflet each time you start a new pen rather than assuming the rules are the same as the previous strength.

It's worth noting that storage applies to the licensed, dispensed pen. Vials or syringes of semaglutide solution described in terms of millilitres ("5 ml", "10 ml") are not a licensed UK weight-management product, and the MHRA has warned publicly about unlicensed and counterfeit semaglutide circulating online. If you've seen a listing for semaglutide by the millilitre without a prescription requirement, that is a red flag worth reporting at the MHRA's Yellow Card service. Genuine Wegovy arrives in a named pre-filled pen, dispensed by a GPhC-registered pharmacy following a prescriber's authorisation.

For a broader picture of how the treatment fits into a weight-management plan, the semaglutide overview covers eligibility, results evidence and what to expect week by week. If you've been reading about how other patients have found Wegovy, that page pulls together the kind of practical questions that come up most often after the first pen.

Eligibility and what a clinical assessment actually covers

Because semaglutide is a prescription-only medicine, a prescriber has to satisfy themselves that it's clinically appropriate before it can be dispensed. The licensed criteria for Wegovy in the UK are a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone is not the whole picture: the prescriber also looks at your medical history, current medicines and any contraindications.

NICE's appraisal of semaglutide for weight management sets out the clinical evidence base and the conditions under which NHS prescribing is recommended; you can read that at NICE Technology Appraisal TA875. NHS access comes with waiting lists and referral criteria; private treatment through a regulated pharmacy is an alternative for people who don't meet the NHS threshold or don't want to wait. There's no pressure either way, and our prescribers at nume are straightforward about what they can and can't approve.

If you're weighing up whether Wegovy is the right option for you compared with other licensed treatments, the weight-loss treatments overview walks through the landscape clearly. And if you have a specific cost question, the Wegovy pricing and sourcing guide covers what a legitimate private prescription typically involves in terms of fees. When you're ready to take the next step, you can check your eligibility with our prescribers at no cost.